More so than the analysts’ reports, the general publicity surrounding the approval of ABBV/ENTA’s regimen will attract attention to ENTA, which remains a stock that doesn’t get much.
It depends on the label in its entirety. There are too many permutations to speculate about this with much confidence.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.